embolization therapy
ProcedurePatients will undergo embolization alone, which involves temporarily blocking the uterine artery or arteries supplying a hypervascular abnormality using resorbable gelatin fragments.
Other names: embolic agent
NCT Number: NCT07206342
The goal of this clinical trial is to determine the best treatment for patients who experience vaginal bleeding following a premature termination of pregnancy.
The main questions it aims to answer are:
* Evaluate the effectiveness of embolization alone versus embolization followed by aspiration in stopping bleeding * Evaluate its effectiveness in restoring the menstrual cycle. * What are the complications associated with the two procedures? * What is their impact on future fertility?
The researchers will evaluate the patients over a period of 12 months.
Participants will:
* Undergo one of the two procedures (procedure 1: embolization alone and procedure 2: embolization combined with aspiration). * Will participate in regular follow-ups to monitor the risk of recurrence of -bleeding and complications associated with the two treatments * Will undergo imaging tests to assess the persistence of bleeding after the procedure
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Not applicable
CHU de Bordeaux, Bordeaux, France
Ten to 15% of pregnancies end in the first trimester. Voluntary termination of pregnancy and spontaneous miscarriage, the two main causes of pregnancy loss, are managed medically or surgically in order to remove the intrauterine residue and restore a vacant uterus. In cases of incomplete evacuation, uterine retention may persist in approximately 1% of all pregnancies and up to 40% of pregnancy terminations in the second trimester.
The management of uterine retention depends on the clinical presentation and its vascularization on ultrasound. If it is not vascularized or only slightly vascularized, simple aspiration or monitoring is considered. In cases of hypervascularity, treatment is debated given the variable amount of bleeding and the sometimes spontaneously favorable outcome. Doppler criteria (systolic peak velocity, resistance index, or vascular invasion of the myometrium) have been described to select patients who are likely to have a spontaneous favorable outcome from those who require invasive management. In cases of hypervascularized intrauterine retention with negative findings on Doppler ultrasound, performing endometrial aspiration carries a significant risk of severe bleeding during the procedure and is generally preceded by embolization in order to minimize this risk (embolization + aspiration). Aspiration induces adhesions (synechiae) that can impair the patient's future fertility.
Recent publications show the effectiveness of temporary embolization alone using resorbable gelatin fragments to stop bleeding. Our team has reported uterine emptiness rates of approximately 75% at 1 month and 95% at 3 months after embolization alone with resorbable gelatin.
The objective of this study is therefore to evaluate the non-inferiority of embolization alone with resorbable gelatin compared to embolization followed by endometrial aspiration in patients with hypervascularized and hemorrhagic intrauterine retention following premature termination of pregnancy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will undergo embolization alone, which involves temporarily blocking the uterine artery or arteries supplying a hypervascular abnormality using resorbable gelatin fragments.
Other names: embolic agent
Patients will undergo embolization prior to endometrial aspiration. Embolization will be performed in the same manner as in group "Embolization alone" but will be followed within 48 hours by a second procedure to remove the intrauterine residue that will have been devascularized (= deprived of blood) by the embolization.
Other names: endometrial aspiration, intrauterine aspiration, hysteroscopy
Time frame: From baseline to 3 months after procedure
The primary endpoint is clinical success defined by a null uterine cavity on follow-up Doppler ultrasound and no persistent or recurrent bleeding requiring a new procedure
Time frame: From baseline to 1 month
Evaluate the effectiveness of embolization alone versus embolization followed by aspiration at 1 month of follow-up in stopping bleeding in patients with hypervascularized hemorrhagic uterine retention following premature termination of pregnancy.
Time frame: Fom intervention to 90 days after
Complications attributable to procedures within 90 days of admission according to the Clavien-Dindo classification
Time frame: From intervention to 1 month
Measurement of uterine emptiness on Doppler ultrasound at 1 month
Time frame: From intervention to 3 months
Measurement of uterine emptiness on Doppler ultrasound at 3 months
Time frame: From intervention to 12 months
Time between intervention and resumption of menstrual cycle
Time frame: From intervention to 12 months
New pregnancy occurring within 12 months of the patient's admission
Time frame: From intervention to 12 months
Uterine adhesions on hysteroscopy performed for infertility assessment.
Contact information is provided by the study sponsor or research team.
AyseGul Sahan
CONTACT
Marine Faure
CONTACT
University Hospital, Grenoble
Other
Acronym: NIEMBUT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03907735
Dystocia, Female Urogenital Diseases and Pregnancy Complications
Portland, Oregon, United States
View Trial DetailsNCT03074903
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Morristown, New Jersey, United States
View Trial DetailsNCT05840471
Abruptio Placentae, Death
Erbil, Kurdistan Region, Iraq
View Trial DetailsNCT06763380
Uterine Abnormality, Uterine Anomalies
Lahore, Punjab Province, Pakistan
View Trial Details